← Reglamento abierto

cusma.4B.300343.c1040

Disposición: Subpartida 300343 · Vigente desde 2020-07-01 · Se aplica a: todos los corredores

Aprobada en bloque y publicada por FSRC el 2026-11-10; aún no revisada regla por regla por un revisor acreditado (vea la nota de revisión) · Cita: CUSMA Annex 4-B (Global Affairs Canada consolidated text), Annex 4-B, Section B, Chapter 30 Pharmaceutical Products, 3001.20-3003.90

Nota de revisión, tal como se publicó

Parsed by @origin/rulebook-ingest (Annex 4-B adapter); awaiting licensed review. Effective date not stated per provision on the page; the loader sets it from the reviewer’s explicit --effective-from decision (D-91), never a default. Expanded from range 3001.20-3003.90 (OPEN-14). Chapter note: Note 1 : A good of any chapter or heading in Section VI that satisfies one or more of Rules 1 through 8 of this Section shall be treated as an originating good, except as otherwise specified in those rules. Chapter note: Note 2: Notwithstanding Note 1, a good is an originating good if it meets the applicable change in tariff classification or satisfies the applicable value content requirement specified in the rules of origin in this Section. (a) dissolution in water or in another solvent; (b) the elimination of solvents, including solvent water; or (c) the addition or elimination of water of crystallisation. (a)the elimination of not less than 80 percent of the content of existing impurities; or (b) the reduction or elimination of impurities resulting in a good suitable for one or more of the following: (i) as a pharmaceutical, medical, cosmetic, veterinary, or food grade substance, (ii) as a chemical product or reagent for analytical, diagnostic, or laboratory uses, (iii) as an element or component for use in micro-elements, (iv) for specialized optical uses, (v) for non-toxic uses for health and safety; (vi) for biotechnical use (e.g. in cell culturing, in genetic technology, or as a catalyst), (vii) as a carrier used in a separation process, or (viii) for nuclear grade uses. (a) Biological or biotechnological culturing, hybridization or genetic modification of: (i) Micro-organisms (bacteria, viruses (includes phages) etc.), or (ii) Human, animal or plant cells; (b) Production, isolation, or purification of cellular or intercellular structures (such as isolated genes, gene fragments, and plasmids); or (c) Products obtained by fermentation. Edition HS2022 and effective date 2020-07-01 set by FSRC at load (D-91; OPEN-06: the Annex is written against HS 2012 nomenclature; transposition not applied). Approved in bulk on the owner's instruction (FSRC owner (user 480c01a9-b5b3-4a3e-a5d0-223e73975b24), 2026-11-10; D-73).

Edición del Sistema Armonizado: las reglas específicas de producto del Anexo 4-B del T-MEC se redactaron conforme a la edición de 2012 (SA 2012). Esta versión las aplica a los códigos de las tarifas actuales, que siguen la edición de 2022 (SA 2022), sin trasponerlas (pregunta abierta OPEN-06). Cuando un código se creó, dividió o renumeró después de 2012, verifique la regla en el texto oficial.

Nota en lenguaje claro

—

Texto oficial

EN

A change to subheading 3001.20 through 3003.90 from any other subheading, including another subheading within that group.

FR

Un changement aux sous‑positions 3001.20 à 3003.90 de toute autre sous‑position, y compris une autre sous-position à l’intérieur de ce groupe.

ES

No disponible en este idioma

Regla estructurada

Alternativas (basta una)

    • Cambio arancelario desde cualquier otra subpartida
JSON
{
  "source": {
    "url": "https://www.international.gc.ca/trade-commerce/trade-agreements-accords-commerciaux/agr-acc/cusma-aceum/text-texte/04.aspx?lang=eng",
    "sha256": "7e30ee34f87778849e969da6f7c05f8861e45bc0ae454d04ddde39fcd539e1b5",
    "text_en": "A change to subheading 3001.20 through 3003.90 from any other subheading, including another subheading within that group.",
    "text_fr": "Un changement aux sous‑positions 3001.20 à 3003.90 de toute autre sous‑position, y compris une autre sous-position à l’intérieur de ce groupe.",
    "citation": "CUSMA Annex 4-B (Global Affairs Canada consolidated text), Annex 4-B, Section B, Chapter 30 Pharmaceutical Products, 3001.20-3003.90",
    "retrieved_at": "2026-11-02T04:21:43.558Z"
  },
  "rule_id": "cusma.4B.300343.c1040",
  "agreement": "CUSMA",
  "effective": {
    "to": null,
    "from": "2020-07-01"
  },
  "applies_to": {
    "code": "300343",
    "level": "subheading"
  },
  "hs_edition": "HS2022",
  "party_scope": "all",
  "alternatives": [
    {
      "all_of": [
        {
          "tariff_shift": {
            "from": "any_other_subheading"
          }
        }
      ]
    }
  ]
}

Historial de versiones

cusma-annex4b-2026-11-r5 v2.1.02026-11-10cusma.4B.300343.c1040agregada